Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,872 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05524090Recruiting
Program to prepare for surgery in locally advanced pancreatic cancer
This trial studies an “implementation program” to help patients with locally advanced pancreatic cancer get ready for the next steps after chemotherapy. It may help improve care planning and outcomes for people whose cancer has not grown after initial treatment.
Amsterdam, North HollandAges 18 years+ - NCT06574620Recruiting
Studying tumor DNA and proteins in pancreatic cancer
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
Vancouver, British ColumbiaAges 18 years+ - NCT06673017RecruitingPhase 1
Testing a new treatment for pancreatic cancer before surgery
This trial tests a new treatment, PTM-101, placed during a laparoscopy procedure for people with pancreatic cancer that can be removed with surgery. It aims to see if adding this treatment before standard chemotherapy helps improve outcomes.
Newport Beach, CaliforniaAges 18 years+ - NCT05053971RecruitingPhase 1/Phase 2
Entinostat plus ZEN003694 for advanced solid tumors
This Phase 1/2 study tests a new combination anti-cancer treatment (entinostat plus ZEN003694) in people with advanced solid tumors that can’t be controlled with standard care. It aims to find a safe dose and see whether the treatment can shrink tumors or control the disease.
New Haven, ConnecticutAges 18 years+ - NCT07090499RecruitingPhase 1
Study of PF-08046876 for advanced solid tumors
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Duarte, CaliforniaAges 18 years+ - NCT03608631RecruitingPhase 1/Phase 2
Exosome treatment for KRAS-mutated metastatic pancreatic cancer
This Phase 1/2 study tests an investigational treatment made from “exosomes” for people with metastatic pancreatic cancer that has a specific KRAS mutation (KRAS G12D). It aims to see if this treatment can control the cancer and is safe for patients whose cancer has grown or stayed the same after prior chemotherapy.
Houston, TexasAges 18 years+ - NCT04605913RecruitingPhase 1/Phase 2
Testing a new combination chemo plus portable TTF therapy for pancreatic cancer
This trial tests a combination of chemotherapy drugs plus a portable TTF device (TTF-100L) to treat pancreatic cancer that has spread to the liver. It may help by trying to shrink or control the cancer in people who haven’t already had treatment specifically for stage IV metastatic disease.
Jacksonville, FloridaAges 18 years+ - NCT07349537RecruitingPhase 1
Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
New Haven, ConnecticutAges 18 years+ - NCT06648434RecruitingPhase 1
MK2 inhibitor plus mFOLFIRINOX for metastatic pancreatic cancer
This trial tests an experimental drug called zunsemetinib (an MK2 inhibitor) combined with a standard chemotherapy regimen (mFOLFIRINOX) for people with pancreatic cancer that has spread to other organs. The goal is to see if the combination works better than chemotherapy alone.
St Louis, MissouriAges 18 years+ - NCT07214298RecruitingPhase 1/Phase 2
Combination study of pegcetacoplan and FOLFIRINOX for metastatic pancreatic cancer
This trial tests a new drug called pegcetacoplan combined with a standard chemotherapy regimen (FOLFIRINOX) for people with pancreatic cancer that has spread. The goal is to see if adding pegcetacoplan makes the treatment more effective.
Buffalo, New YorkAges 18 years+ - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Scottsdale, ArizonaAges 18 years+ - NCT06265285RecruitingPhase 2
Nivolumab at home vs. clinic for cancer treatment
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
Jacksonville, FloridaAges 18 years+ - NCT07269626RecruitingPhase 2
PULSAR therapy for pancreatic cancer
This trial tests whether adding a special type of radiation therapy (PULSAR) to standard chemotherapy can help control pancreatic cancer that has not spread far. It is for people who have already completed a few rounds of chemo without their cancer growing.
Seoul, Select Province/StateAges 19 years+ - NCT06904378RecruitingPhase 1/Phase 2
New drug combo for advanced pancreatic cancer
This trial tests a new drug called ONT01 combined with two standard chemo drugs (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that has spread and is no longer responding to first treatment. The goal is to see if this new combination can help control the cancer.
St Louis, MissouriAges 18 years+ - NCT06649292RecruitingPhase 3
Study of SHR-A1904 for gastric cancer with CLDN18.2
This trial tests a new drug called SHR-A1904 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has already been treated once. It is for those whose tumors are positive for a protein called CLDN18.2.
Guangzhou, GuangdongAges 18–75 - NCT06229496RecruitingPhase 1
Study of GAS for newly diagnosed advanced pancreatic cancer
This trial tests an oral medication called GAS in people with pancreatic cancer that has spread to other parts of the body, who have not yet received any treatment for metastatic disease. The goal is to find the best dose and see how well it works.
Chiayi CityAges 18 years+ - NCT06278545RecruitingPhase 2
Chemotherapy for unremovable small bowel cancer
This trial tests two standard chemotherapy combinations (FOLFIRINOX and FOLFOX) in people with small bowel adenocarcinoma that cannot be removed by surgery or has spread. It aims to see which works better for people who haven't had chemotherapy before.
DijonAges 18 years+ - NCT07232875RecruitingPhase 3
New drug combo for first-line advanced pancreatic cancer
This trial tests a new drug (HRS-4642) combined with standard chemotherapy as a first treatment for advanced pancreatic cancer that has spread. It may help shrink tumors and extend life.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06747845RecruitingPhase 2
Maintenance therapy for stable metastatic pancreatic cancer
This trial tests a combination of two drugs, niraparib and ipilimumab, as a maintenance treatment for people with metastatic pancreatic cancer that has not grown after initial chemotherapy. The goal is to see if this can help keep the cancer stable longer.
Boston, MassachusettsAges 18 years+ - NCT07490301RecruitingPhase 2/Phase 3
Study of a new drug combo for first-line metastatic pancreatic cancer
This trial tests a new targeted drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for people with advanced pancreatic cancer that has spread. The goal is to see if this combination works better than current treatments.
Chicago, IllinoisAges 18 years+ - NCT06825546RecruitingPhase 2
Icaritin plus chemo for advanced pancreatic cancer
This trial tests a new combination of a plant-based drug (icaritin) and two chemotherapy drugs (AG) for people with advanced pancreatic cancer who have not had treatment before. The goal is to see if the combination works better than chemotherapy alone.
Guangzhou, GuangdongAges 18–80 - NCT07723261Recruiting
Testing NalIriFOx as first treatment for metastatic pancreatic cancer
This trial is testing a drug combination called NalIriFOx as the first treatment for people with pancreatic cancer that has spread. The goal is to see if it is safe and works well over the long term.
AthensAges 18 years+ - NCT07165951RecruitingPhase 3
Study of new drug combo for first treatment of advanced pancreatic cancer
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
Hefei, AnhuiAges 18–75 - NCT07483983RecruitingPhase 2
Study of ASP3082 for advanced lung and pancreatic cancers with KRAS G12D mutation
This trial tests a new drug, ASP3082, for people with advanced non-small cell lung cancer or pancreatic cancer that has a specific gene change called KRAS G12D. The study will collect tumor and blood samples to understand how the cancer responds or becomes resistant to the treatment.
Villejuif, FranceAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,872 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.